Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation

Table 1

Patient Demographics and Baseline Characteristics.

	Tacrolimus/Sirolimus $N=318$	Tacrolimus/MMF $N=316$
Recipients
Age, mean (SD), y	44.3 (11.3)	44.9 (11.1)
Range, y	18–66	18–72
Male, Number (%)	204 (64.2)	204 (64.6)
Race, Number (%)
Caucasian	299 (94.0)	303 (95.9)
Black	10 (3.1)	7 (2.2)
Oriental	7 (2.2)	4 (1.3)
Other	2 (0.6)	2 (0.6)
Previous transplants, Number (%)
0	306 (96.2)	301 (95.3)
1	12 (3.8)	14 (4.4)
3	0 (0.0)	1 (0.3)
${\text{PRA}}^{\text{a}}$: 0%–50%, Number (%)	316 (99.7)	313 (100.0)
50%–100%, Number (%)	1 (0.3)	0 (0.0)
Donors
Donation type: Number (%)
Living	41 (12.9)	32 (10.1)
Deceased	277 (87.1)	284 (89.9)
Transplant
ABO identical, Number (%)	296 (93.1)	295 (93.4)
Cold ischemia time, mean (SD), h	16.1 (6.1)	16.0 (5.8)
Mean total HLA mismatch	2.9	3.0
CMV status: Donor +/Recipient $-$, Number (%)	47 (14.8)	57 (18.0)

FAS
${}_{}{}^{\text{a}}\text{PRA}$ not recorded for all patients.